Company Revenue Reports

The company grew nearly 30% in 1H21 but has not yet achieved volumes seen in 2019. MicroPort did, however, make important gains in China.

The company declined in the mid-single digits in 1H21 due to market instability caused by China's volume-based procurement policy.

In 2Q21, the company regained much of its pre-pandemic growth momentum except for a lagging recovery in Italy.

The company's FY 1Q22 saw double-digit growth in its spine business, driven by strength in biologics and recovering surgical volumes.

The company grew nearly 30% in the first half of 2021, with important contributions coming from its growing presence in the U.S. market.

The company closed its 2021 fiscal year up high single digits compared to 2020 but is still well below historical norms.

The company reported more than 35% growth in the first half of 2021 with gains driven by new products and an expanded salesforce.

The company improved in 2Q21 vs. last year but is dealing with regulatory and organization issues from the sale of its OEM business

The company benefitted from $41 million in one-time royalty and settlement payments in 2Q21 but its product revenue remains down vs. 2019.

The company's revenue grew double-digits in 2Q21 on the strength of share gains instead of recapturing backlogged procedures.